These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 15228236

  • 1. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL, Malek SK, Prichard JW, Lin F, Yahya TM, Schwartzman MS, Latsha RP, Skaletsky M, Norfolk ER, Brown RE, Hartle JE, Potdar S.
    Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
    [Abstract] [Full Text] [Related]

  • 2. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL, Malek SK, Blasick TM, Pennington JR, Masker KK, Lun M, Potdar S.
    Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
    [Abstract] [Full Text] [Related]

  • 3. Campath-1H use in pediatric renal transplantation.
    Bartosh SM, Knechtle SJ, Sollinger HW.
    Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
    Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G.
    Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, Roth D, Ruiz P, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2004 Aug 15; 78(3):426-33. PubMed ID: 15316372
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.
    Transplantation; 2007 Jun 15; 83(11):1509-12. PubMed ID: 17565326
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.